PMID- 37375813
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230701
IS  - 1424-8247 (Print)
IS  - 1424-8247 (Electronic)
IS  - 1424-8247 (Linking)
VI  - 16
IP  - 6
DP  - 2023 Jun 11
TI  - Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research 
      Advances.
LID - 10.3390/ph16060866 [doi]
LID - 866
AB  - BACKGROUND: While current clinically administered anticoagulant medications have 
      demonstrated effectiveness, they have also precipitated significant risks: severe 
      bleeding complications including, but not limited to, gastrointestinal 
      hemorrhaging and intracranial and other life-threatening major bleedings. An 
      ongoing effort is being made to identify the best targets for 
      anticoagulant-targeted drugs. Coagulation factor XIa (FXIa) is emerging as an 
      important target of current anticoagulant treatment. OBJECTIVE: This review will 
      summarize the development of anticoagulants and recent advances in clinical 
      trials of experimental factor XI inhibitors from a clinical application 
      perspective. RESULTS: As of 1 January 2023, our search screening included 33 
      clinical trials. We summarized the research progress of FXIa inhibitors from 
      seven clinical trials that evaluated their efficacy and safety. The results 
      showed no statistically meaningful distinction in the primary efficacy between 
      patients receiving FXIa inhibitors compared to controls (RR = 0.796; 95% CI: 
      0.606-1.046; I(2) = 68%). The outcomes did not indicate a statistical difference 
      in the occurrence of any bleeding between patients receiving FXIa inhibitors 
      compared to controls (RR = 0.717; 95% CI: 0.502-1.023; I(2) = 60%). A subgroup 
      analysis found significant differences in severe bleeding and clinically relevant 
      hemorrhaging in subjects receiving FXIa inhibitors compared to Enoxaparin (RR = 
      0.457; 95% CI: 0.256-0.816; I(2) = 0%). CONCLUSIONS: Clinical trials to date have 
      indicated that factor XIa is a potential anticoagulation target, and factor XIa 
      inhibitors may play an important role in the development of anticoagulants.
FAU - Xia, Yunqing
AU  - Xia Y
AUID- ORCID: 0000-0002-9416-4684
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, 
      China.
FAU - Hu, Yu
AU  - Hu Y
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, 
      China.
AD  - Collaborative Innovation Center of Hematology, Huazhong University of Science and 
      Technology, Wuhan 430022, China.
FAU - Tang, Liang
AU  - Tang L
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, 
      China.
LA  - eng
GR  - No.2022YFC2304600/the National Key R&D Program of China/
GR  - No. 81973995/the National Natural Science Foundation of China/
GR  - No. 82170131/the National Natural Science Foundation of China/
GR  - No. 2018QYTD14/the Program for HUST Academic Frontier Youth Team/
GR  - 202117/the Young Top-notch Talent Cultivation Program of Hubei Province/
PT  - Journal Article
PT  - Review
DEP - 20230611
PL  - Switzerland
TA  - Pharmaceuticals (Basel)
JT  - Pharmaceuticals (Basel, Switzerland)
JID - 101238453
PMC - PMC10300994
OTO - NOTNLM
OT  - XIa
OT  - clinical trials
OT  - venous thromboembolism
COIS- The authors declare no conflict of interest.
EDAT- 2023/06/28 06:42
MHDA- 2023/06/28 06:43
PMCR- 2023/06/11
CRDT- 2023/06/28 01:35
PHST- 2023/04/17 00:00 [received]
PHST- 2023/06/03 00:00 [revised]
PHST- 2023/06/04 00:00 [accepted]
PHST- 2023/06/28 06:43 [medline]
PHST- 2023/06/28 06:42 [pubmed]
PHST- 2023/06/28 01:35 [entrez]
PHST- 2023/06/11 00:00 [pmc-release]
AID - ph16060866 [pii]
AID - pharmaceuticals-16-00866 [pii]
AID - 10.3390/ph16060866 [doi]
PST - epublish
SO  - Pharmaceuticals (Basel). 2023 Jun 11;16(6):866. doi: 10.3390/ph16060866.